FDA expands Zytiga's use for late-stage prostate cancer

News
Article

FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.